<html class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers no-applicationcache svg inlinesvg smil svgclippaths" lang="en-US"><head>
  <meta charset="utf-8">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link href="https://fonts.googleapis.com/css?family=Montserrat:400,600,700" rel="stylesheet" type="text/css">

    <link rel="icon" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/favicon.ico">
  <link rel="apple-touch-icon" sizes="57x57" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-57x57.png">
  <link rel="apple-touch-icon" sizes="60x60" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-60x60.png">
  <link rel="apple-touch-icon" sizes="72x72" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-72x72.png">
  <link rel="apple-touch-icon" sizes="76x76" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-76x76.png">
  <link rel="apple-touch-icon" sizes="114x114" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-114x114.png">
  <link rel="apple-touch-icon" sizes="120x120" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-120x120.png">
  <link rel="apple-touch-icon" sizes="144x144" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-144x144.png">
  <link rel="apple-touch-icon" sizes="152x152" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-152x152.png">
  <link rel="apple-touch-icon" sizes="180x180" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/apple-touch-icon-180x180.png">
  <link rel="icon" type="image/png" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/favicon-32x32.png" sizes="32x32">
  <link rel="icon" type="image/png" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/android-chrome-192x192.png" sizes="192x192">
  <link rel="icon" type="image/png" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/favicon-96x96.png" sizes="96x96">
  <link rel="icon" type="image/png" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/favicon-16x16.png" sizes="16x16">
  <link rel="manifest" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/manifest.json">
  <link rel="mask-icon" href="https://kodiak.com/wp-content/themes/kodiaker/favicon/safari-pinned-tab.svg" color="#2a8ed6">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-TileImage" content="https://kodiak.com/wp-content/themes/kodiaker/favicon/mstile-144x144.png">
  <meta name="theme-color" content="#ffffff">

  <meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">

	<!-- This site is optimized with the Yoast SEO plugin v16.6.1 - https://yoast.com/wordpress/plugins/seo/ -->
	<title>Our Pipeline - Kodiak Sciences</title>
	<link rel="canonical" href="https://kodiak.com/our-pipeline/">
	<meta property="og:locale" content="en_US">
	<meta property="og:type" content="article">
	<meta property="og:title" content="Our Pipeline - Kodiak Sciences">
	<meta property="og:url" content="https://kodiak.com/our-pipeline/">
	<meta property="og:site_name" content="Kodiak Sciences">
	<meta property="article:modified_time" content="2022-06-06T17:47:10+00:00">
	<meta name="twitter:card" content="summary_large_image">
	<script async="" src="//www.google-analytics.com/analytics.js"></script><script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"https://kodiak.com/#website","url":"https://kodiak.com/","name":"Kodiak Sciences","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://kodiak.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https://kodiak.com/our-pipeline/#webpage","url":"https://kodiak.com/our-pipeline/","name":"Our Pipeline - Kodiak Sciences","isPartOf":{"@id":"https://kodiak.com/#website"},"datePublished":"2018-09-20T19:11:26+00:00","dateModified":"2022-06-06T17:47:10+00:00","breadcrumb":{"@id":"https://kodiak.com/our-pipeline/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://kodiak.com/our-pipeline/"]}]},{"@type":"BreadcrumbList","@id":"https://kodiak.com/our-pipeline/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://kodiak.com/"},{"@type":"ListItem","position":2,"name":"Our Pipeline"}]}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel="dns-prefetch" href="//s.w.org">
<script type="text/javascript">
window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/kodiak.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.0"}};
/*! This file is auto-generated */
!function(e,a,t){var n,r,o,i=a.createElement("canvas"),p=i.getContext&&i.getContext("2d");function s(e,t){var a=String.fromCharCode,e=(p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,e),0,0),i.toDataURL());return p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,t),0,0),e===i.toDataURL()}function c(e){var t=a.createElement("script");t.src=e,t.defer=t.type="text/javascript",a.getElementsByTagName("head")[0].appendChild(t)}for(o=Array("flag","emoji"),t.supports={everything:!0,everythingExceptFlag:!0},r=0;r<o.length;r++)t.supports[o[r]]=function(e){if(!p||!p.fillText)return!1;switch(p.textBaseline="top",p.font="600 32px Arial",e){case"flag":return s([127987,65039,8205,9895,65039],[127987,65039,8203,9895,65039])?!1:!s([55356,56826,55356,56819],[55356,56826,8203,55356,56819])&&!s([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]);case"emoji":return!s([129777,127995,8205,129778,127999],[129777,127995,8203,129778,127999])}return!1}(o[r]),t.supports.everything=t.supports.everything&&t.supports[o[r]],"flag"!==o[r]&&(t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&t.supports[o[r]]);t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&!t.supports.flag,t.DOMReady=!1,t.readyCallback=function(){t.DOMReady=!0},t.supports.everything||(n=function(){t.readyCallback()},a.addEventListener?(a.addEventListener("DOMContentLoaded",n,!1),e.addEventListener("load",n,!1)):(e.attachEvent("onload",n),a.attachEvent("onreadystatechange",function(){"complete"===a.readyState&&t.readyCallback()})),(e=t.source||{}).concatemoji?c(e.concatemoji):e.wpemoji&&e.twemoji&&(c(e.twemoji),c(e.wpemoji)))}(window,document,window._wpemojiSettings);
</script><script src="https://kodiak.com/wp-includes/js/wp-emoji-release.min.js?ver=6.0" type="text/javascript" defer=""></script>
<style type="text/css">
img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 0.07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}
</style>
	<link rel="stylesheet" id="all-css-0" href="https://kodiak.com/_static/??-eJyNy0sKgDAMRdENWYP4QQfiWmobJJpWaSrS3duJoDOHl/cOXIcib/i0KGBEwJJEmHk3m2Kagw4JJCbG0pEv86GAt1gFHFrSyOjQx08crBMGxbhok/7xvL37QZMbq66th3rom/4Gh8tBuQ==" type="text/css" media="all">
<style id="wp-block-library-inline-css">
.has-text-align-justify{text-align:justify;}
</style>
<style id="global-styles-inline-css">
body{--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel="stylesheet" id="all-css-2" href="https://kodiak.com/_static/??/wp-content/plugins/contact-form-7/includes/css/styles.css,/wp-content/themes/kodiaker/dist/styles/main-9af9e269.css?m=1652205567" type="text/css" media="all">
<!--[if lte IE 9]>
<link rel='stylesheet' id='sage_css_ie9-css'  href='https://kodiak.com/wp-content/themes/kodiaker/dist/styles/mainie9.css' media='all' />
<![endif]-->
<link rel="stylesheet" id="all-css-4" href="https://kodiak.com/wp-content/mu-plugins/jetpack-11.0/css/jetpack.css?m=1654261646g" type="text/css" media="all">
<script type="text/javascript" src="https://kodiak.com/_static/??-eJzTLy/QzcxLzilNSS3WzwKiwtLUokoopZebmaeXVayjj0+Rbm5melFiSSpUsX2uraGZqbGlsaWFiUUWAK+/IjA="></script><link rel="https://api.w.org/" href="https://kodiak.com/wp-json/"><link rel="alternate" type="application/json" href="https://kodiak.com/wp-json/wp/v2/pages/840"><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://kodiak.com/xmlrpc.php?rsd">
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://kodiak.com/wp-includes/wlwmanifest.xml"> 
<meta name="generator" content="WordPress 6.0">
<link rel="shortlink" href="https://kodiak.com/?p=840">
<link rel="alternate" type="application/json+oembed" href="https://kodiak.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fkodiak.com%2Four-pipeline%2F">
<link rel="alternate" type="text/xml+oembed" href="https://kodiak.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fkodiak.com%2Four-pipeline%2F&amp;format=xml">
<style>img#wpstats{display:none}</style>
	<style type="text/css">.recentcomments a{display:inline !important;padding:0 !important;margin:0 !important;}</style>
    <script>
	(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	})(window,document,'script','//www.google-analytics.com/analytics.js','ga');

	ga('create', 'UA-71146718-1', 'auto');
	ga('send', 'pageview');

  </script>
  </head>
  	<body class="page-template page-template-page_templates page-template-pipeline page-template-page_templatespipeline-php page page-id-840 our-pipeline">
  	<!--[if lt IE 9]>
	  <div class="alert alert-warning">
		You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.	  </div>
	<![endif]-->
	<div id="canvas-resetter"></div>
	<nav id="offcanvas-navigation" role="navigation">
	  <div class="menu-primary-nav-container"><ul id="menu-primary-nav" class="nav"><li id="menu-item-816" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-816"><a href="https://kodiak.com/our-company/">Our Company</a></li>
<li id="menu-item-839" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-839"><a href="https://kodiak.com/our-science/">Our Science</a></li>
<li id="menu-item-843" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-840 current_page_item menu-item-843"><a href="https://kodiak.com/our-pipeline/">Our Products</a></li>
<li id="menu-item-913" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-913"><a href="https://kodiak.com/working-at-kodiak/">Join Us</a></li>
<li id="menu-item-1279" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-1279"><a href="https://ir.kodiak.com">Investors &amp; Media<button type="button" class="menu-item-toggle icon-menu-toggle js-menu-item-toggle"><span class="sr-only">Toggle</span></button></a>
<ul class="sub-menu">
	<li id="menu-item-1554" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1554"><a href="https://ir.kodiak.com/">Overview</a></li>
	<li id="menu-item-1555" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1555"><a href="https://ir.kodiak.com/news-releases">Press Releases</a></li>
	<li id="menu-item-1556" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1556"><a href="https://ir.kodiak.com/events-and-presentations/events">Events and Presentations</a></li>
	<li id="menu-item-1281" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1281"><a href="https://ir.kodiak.com/stock-information/stock-quote-chart">Stock Information</a></li>
	<li id="menu-item-1282" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1282"><a href="https://ir.kodiak.com/financial-information/analyst-coverage">Analyst Coverage</a></li>
	<li id="menu-item-1476" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1476"><a href="https://ir.kodiak.com/financial-information/sec-filings">SEC Filings</a></li>
	<li id="menu-item-1283" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1283"><a href="https://ir.kodiak.com/corporate-governance/governance-overview">Corporate Governance</a></li>
	<li id="menu-item-1284" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1284"><a href="https://ir.kodiak.com/shareholder-services/investor-faqs">Investor Resources</a></li>
</ul>
</li>
</ul></div>	</nav>
	<header id="site-header" role="banner">
  <div class="container-fluid">
	<a class="brand left" href="https://kodiak.com/">Kodiak Sciences</a>
	<button type="button" class="navbar-toggle btn-nostyle" id="primary-navigation-toggle">
	  <span class="sr-only">Toggle navigation</span>
	  <span class="icon-bar"></span>
	  <span class="icon-bar"></span>
	  <span class="icon-bar"></span>
	</button>
	<button type="button" class="close" aria-label="Close">
	  <div class="modal-x modal-x-a"></div>
	  <div class="modal-x modal-x-b"></div>
	</button>
	<nav id="primary-navigation" class="right" role="navigation">
	  <div class="menu-primary-nav-container"><ul id="menu-primary-nav-1" class="nav"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-816"><a href="https://kodiak.com/our-company/">Our Company</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-839"><a href="https://kodiak.com/our-science/">Our Science</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-840 current_page_item menu-item-843"><a href="https://kodiak.com/our-pipeline/" aria-current="page">Our Products</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-913"><a href="https://kodiak.com/working-at-kodiak/">Join Us</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-1279"><a href="https://ir.kodiak.com">Investors &amp; Media</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1554"><a href="https://ir.kodiak.com/">Overview</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1555"><a href="https://ir.kodiak.com/news-releases">Press Releases</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1556"><a href="https://ir.kodiak.com/events-and-presentations/events">Events and Presentations</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1281"><a href="https://ir.kodiak.com/stock-information/stock-quote-chart">Stock Information</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1282"><a href="https://ir.kodiak.com/financial-information/analyst-coverage">Analyst Coverage</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1476"><a href="https://ir.kodiak.com/financial-information/sec-filings">SEC Filings</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1283"><a href="https://ir.kodiak.com/corporate-governance/governance-overview">Corporate Governance</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1284"><a href="https://ir.kodiak.com/shareholder-services/investor-faqs">Investor Resources</a></li>
</ul>
</li>
</ul></div>	</nav>
  </div>
</header>
	<div id="offcanvas-wrapper" class="offcanvas">
	  	  <div class="wrap" role="document">
		<div class="content clearfix">
		  <main role="main">
	  			

	<div class="banner-img-wrap banner-img-wrap-gallery banner-img-wrap-leadership">
    <div class="banner banner-img banner-img-fg" style="background-image:url(https://kodiak.com/wp-content/uploads/sites/2/2016/01/bg_about2-e1463438172990.png)">
      <div class="container-fluid">
        <div class="row tight-row no-pad-md">
          <div class="col-xs-12 col-xs-offset-0 col-sm-10 col-md-6 col-md-offset-6">
            <h1 class="gallery-page-header">Generation 2.0</h1>
            <p class="gallery-descr">Inspired to build the world's leading high-science retina pipeline</p>
          </div>
        </div>
      </div>
    </div></div>
	
	<article class="pipeline">
							<div class="pipeline-image-section" style="background-image:url('https://kodiak.com/wp-content/uploads/sites/2/2020/08/Kodiak_Banner_2021-Vision-scaled.jpg?w=2560');">
				<div class="container-fluid">
											<h1 class="underlined-title underlined-title-centered underlined-title-text-light">Our Vision</h1>
																<div class="pipeline-fw-image">
							<img src="https://kodiak.com/wp-content/uploads/sites/2/2022/05/2022-vision-update-v7.png?w=2560">
						</div>
									</div>
			</div>
		
		<div class="toggle-chart">
			<div class="container-fluid">
				<div class="toggle-chart-row toggle-chart-row--heading clearfix">
					<div class="toggle-chart-heading toggle-chart-col toggle-chart-col--1">
						Product candidate					</div>
					<div class="toggle-chart-col toggle-chart-col--2">
						<div class="toggle-chart-heading toggle-chart-col">
							Pre-clinical						</div>
						<div class="toggle-chart-heading toggle-chart-col">
							Pre-IND						</div>
						<div class="toggle-chart-heading toggle-chart-col">
							Phase 1a/1b						</div>
						<div class="toggle-chart-heading toggle-chart-col">
							Phase 3						</div>
					</div>
				</div>
			</div>
							<div class="container-fluid">
											<div class="toggle-chart-row toggle-chart-row--title">
						<p><strong>KSI-301</strong> anti-VEGF biopolymer conjugate</p>
						</div>
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="1">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Wet age-related macular degeneration</span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-1">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																	<section class="pipeline-image-text-overlay" style="background-image: url(https://kodiak.com/wp-content/uploads/sites/2/2015/10/kodiak_womanatsink.jpg?w=1280);">
											<span class="pipeline-image-text-overlay-text">“For the first few months, my vision improved with monthly visits and injections. But it’s difficult to have family members take me to my appointments, and I can’t make it to the office that often anymore. My vision is slowly getting worse.” </span>
										</section>
																																																																																																		<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">What is WET AMD?</h1>
													<div class="pipeline-text-title-text">
														<p class="p1"><span style="font-weight: 400">Age-related macular degeneration (AMD) is a common degenerative disease of the retina, the light-sensitive tissue in the back of the eye. Wet AMD occurs when the abnormal blood vessels (choroidal neovascularization) grow underneath the macula leading to leakage of fluid and blood leading to visual distortion and acute vision loss. If untreated or undertreated, wet AMD leads to scar formation and permanent damage that results in blindness. Wet AMD is the leading cause of vision loss among individuals 50 years of age and older in the United States and other developed countries.</span></p>
													</div>
												</div>
											</div>
										</section>
																																																																																																																					<section class="pipeline-text-images-wrap">
												<div class="row">
													<div class="col-xs-12 col-sm-10 col-sm-offset-1">
																																								<section class="pipeline-text-images-outside">
															<div class="pipeline-text-images">
																																	<div class="pipeline-text-images-col pipeline-text-images-images">
																	<img width="1444" height="1219" src="https://kodiak.com/wp-content/uploads/sites/2/2018/10/Our-Pipeline_Graph_1-1.png?w=1444" class="attachment-kosci_hero-fw size-kosci_hero-fw" alt="" loading="lazy">																	</div>
																																																<div class="pipeline-text-images-col pipeline-text-images-text">
																																		<div class="pipeline-text-images-text-wrap">
																		<p class="p1"><b>Are there medicines available to treat wet AMD? </b></p>
<p><span style="font-weight: 400">Excess VEGF levels inside the eye play a role in the development of abnormal blood vessels in wet AMD. Current standard of care involves frequent injections in the eye (intravitreal injections), often every 4 to 8 weeks, that block VEGF.</span></p>
																	</div>
																</div>
															</div>
														</section>
																											<section class="pipeline-text-images-outside">
															<div class="pipeline-text-images">
																																	<div class="pipeline-text-images-col pipeline-text-images-images">
																	<img width="1444" height="1219" src="https://kodiak.com/wp-content/uploads/sites/2/2022/05/slide8.png?w=1444" class="attachment-kosci_hero-fw size-kosci_hero-fw" alt="" loading="lazy">																	</div>
																																																<div class="pipeline-text-images-col pipeline-text-images-text pipeline-text-images-text--legend">
																																			<div class="pipeline-text-images-legend">
																			<img width="114" height="297" src="https://kodiak.com/wp-content/uploads/sites/2/2022/05/Our_Pipeline_Arrows_GivenDose.png" class="attachment-full size-full" alt="" loading="lazy">																		</div>
																																		<div class="pipeline-text-images-text-wrap">
																		<p class="p1"><b>Are these medicines effective?</b></p>
<p><span style="font-weight: 400">Although intravitreal injections of anti-VEGF agents can be effective, the frequent visits to the doctor’s office are burdensome and difficult to maintain. Non-compliance to these regimens results in vision loss from undertreatment.&nbsp;</span></p>
<p><span style="font-weight: 400">Each time the treatment interval is overextended, the patient’s </span><span style="font-weight: 400">disease can reactivate, which leads to incremental and cumulative </span><span style="font-weight: 400">damage to the retina. Over time this may lead to permanent loss of vision.</span></p>
																	</div>
																</div>
															</div>
														</section>
																										</div>
												</div>
											</section>
																																										</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">How KSI-301 Can Help</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Our therapeutic candidate KSI-301 is a novel anti-VEGF biologic built on our propriety antibody biopolymer conjugate (ABC) platform.&nbsp;</span></p>
<p>KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. Primary results of the Phase 2b/3 DAZZLE study, evaluating KSI-301’s efficacy, durability and safety, are now available <a style="text-decoration: underline" href="https://ir.kodiak.com/static-files/eaf9070c-6733-4e4b-8a92-eba1719a4c8d">here</a>.</p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="1">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
														<div class="container-fluid">
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="2">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Diabetic macular edema </span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-2">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																	<section class="pipeline-image-text-overlay" style="background-image: url(https://kodiak.com/wp-content/uploads/sites/2/2018/10/Our-Pipeline_KSI-301_Header-01.png?w=2560);">
											<span class="pipeline-image-text-overlay-text">“My diabetes began affecting my vision about a year ago. Recently, it got much worse. My doctor told me that I need to come in ten times in the first year for treatment, but I know I can’t do that with my schedule.” </span>
										</section>
																																																																																																		<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">What is Diabetic Macular Edema (DME)?</h1>
													<div class="pipeline-text-title-text">
														<p class="p1">The worldwide diabetes epidemic is putting more working-age individuals at risk of blindness.</p>
<p class="p1">Diabetes is the leading cause of blindness among working-age adults. Diabetic retinopathy (DR) is a complication of diabetes. Long-standing elevated blood sugar levels (hyperglycemia) due to diabetes damages blood vessels in the retina and cause them to leak fluid into the retina. Elevated levels of intraocular VEGF play a role in the development and progression of DR.</p>
<p class="p1">Diabetic macular edema (DME) is a complication of diabetic retinopathy. DME is the most common cause of vision loss in patients with diabetic retinopathy. Abnormal leakage and fluid from damaged blood vessels accumulate in the macula, the region within retina responsible for central vision, and result in blurry vision. DME can occur at any stage of diabetic retinopathy.</p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">KSI-301 for DME</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Our therapeutic candidate KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to </span><span style="font-weight: 400">have extended ocular half-life, higher potency, and improved ocular tissue bioavailability.&nbsp;</span></p>
<p><span style="font-weight: 400">KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. </span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="2">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
														<div class="container-fluid">
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="3">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Retinal vein occlusion </span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-3">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																	<section class="pipeline-image-text-overlay" style="background-image: url(https://kodiak.com/wp-content/uploads/sites/2/2020/07/new-drawer-image-blue.jpg?w=2380);">
											<span class="pipeline-image-text-overlay-text">“I suddenly noticed blurry vision in one eye, and it got much worse over the course of a couple days. My doctor diagnosed me with a retinal vein occlusion and said I can lose my vision permanently without frequent treatment.”</span>
										</section>
																																																																																																		<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">What is Retinal Vein Occlusion (RVO)?</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">The retina needs a constant supply of oxygen and nutrients delivered by blood vessels. In retinal vein occlusion (RVO), a blockage occurs in either the central retinal vein (CRVO) or a branch retinal vein (BRVO). As a result of the RVO, ischemia develops within the retina and VEGF levels are elevated. Patients with RVO are at risk for developing:&nbsp;</span></p>
<ul>
<li class="p1"><span style="font-weight: 400">Macular edema: Fluid leakage into the center of the retina causing decreased vision </span></li>
<li class="p1"><span style="font-weight: 400">Retinal and Anterior Segment Neovascularization: Abnormal, blood vessels grow in response to ischemia and excess VEGF. Neovascularization easily </span><span style="font-weight: 400">bleeds and may lead to severe vision loss and neovascular glaucoma. </span></li>
</ul>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">KSI-301 FOR RVO</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Our therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia </span><span style="font-weight: 400">due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents </span><span style="font-weight: 400">have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians.&nbsp;</span></p>
<p><span style="font-weight: 400">KSI-301 is being developed towards a once every two months or longer treatment regimen. </span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="3">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
														<div class="container-fluid">
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="4">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Diabetic retinopathy </span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-4">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(88% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																	<section class="pipeline-image-text-overlay" style="background-image: url(https://kodiak.com/wp-content/uploads/sites/2/2020/07/drawerimage.jpg?w=2380);">
											<span class="pipeline-image-text-overlay-text">“I’ve been working to control my diabetes for years. My doctor tells me I now have diabetic retinopathy, and I am on a path to lose my vision”</span>
										</section>
																																																																																																		<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">What is Diabetic Retinopathy?</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Diabetic retinopathy is a complication of diabetes. High blood sugar levels (hyperglycemia) damages and weakens blood vessel in the retina and precedes further complications that irreversibly damage vision.&nbsp;</span></p>
<p><span style="font-weight: 400">Non-proliferative diabetic retinopathy (NPDR) is the early stage of diabetic retinopathy. Many diabetic patients have NPDR which is characterized by weakened blood vessels that lead to microaneurysms. The microaneurysms rupture and form hemorrhages within the retina and weakened blood </span><span style="font-weight: 400">vessels can leak and cause fluid to seep into the retina. These complications this can interfere with the normal function of the macula and cause vision </span><span style="font-weight: 400">loss. As NPDR progresses, vessels eventually become obstructed and block off blood flow.&nbsp;</span></p>
<p><span style="font-weight: 400">Proliferative diabetic retinopathy (PDR) is the more advanced stage of diabetic eye disease. Retinal cells release angiogenic signals (VEGF) to stimulate growth of new retinal blood vessels to bypass the damaged or obstructed vessels (neovascularization). The new vessels are abnormal, fragile and easily tear leading to vitreous hemorrhage and sudden vision loss.</span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">KSI-301 for Diabetic Retinopathy</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Our therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians.&nbsp;</span></p>
<p><span style="font-weight: 400">KSI-301 is being developed towards a once every four to six-month treatment regimen – a possible gamechanger that may provide the opportunity for real prevention.</span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="4">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
										<div class="container-fluid">
						<div class="toggle-chart-row toggle-chart-row--divider">
							<p></p>
						</div>
					</div>
														<div class="container-fluid">
											<div class="toggle-chart-row toggle-chart-row--title">
						<p><strong>KSI-501</strong> anti-IL6 and anti-VEGF bispecific biopolymer conjugate</p>
						</div>
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="5">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Retinal vascular diseases featuring an inflammatory component</span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(43% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-5">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(43% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">How does inflammation contribute to retinal diseases?</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">In addition to abnormal vessel growth (angiogenesis), inflammation has been implicated in the pathogenesis of several retinal diseases. Anti- inflammatory therapies such as steroids have been effective in treating both uveitis (a spectrum of diseases with intraocular inflammation as a defining characteristic) and DME. Similarly, genetically inherited variations in the interleukin 6, or IL-6, gene have been associated with higher PDR incidence in patients with type 2 diabetes.&nbsp;</span></p>
<p><span style="font-weight: 400">Moreover, disease progression in AMD, DR and RVO have been reported to be associated with increased serum and/or ocular levels of IL-6. Additionally, </span><span style="font-weight: 400">chronic inflammatory cells have been seen on the surface of the basement membrane behind the retina in eyes with wet AMD. Interestingly, IL-6 has been implicated in resistance to anti-VEGF treatments in DME patients. This in part is believed to be an indirect result of IL-6 mediated upregulation of VEGF expression as well as more direct VEGF-independent angiogenic functions mediated by IL-6 signaling that occur in the presence of VEGF inhibitors. </span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">How KSI-501 Can Help</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Our KSI-501 product candidate is a dual inhibitor Trap-Antibody-Fusion, or TAF, bioconjugate molecule designed to target concurrent inflammation and </span><span style="font-weight: 400">abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases. KSI-501 acts through an anti-VEGF mechanism and an anti- </span><span style="font-weight: 400">inflammatory mechanism that targets the potent cytokine IL-6. Similar to KSI-301, KSI-501 uses the ABC Platform and is a bioconjugate of the TAF protein conjugated to our phosphorylcholine-based biopolymer. Preclinical binding and functional studies demonstrate that the TAF protein binds specifically and simultaneously to its intended targets. We believe that this dual inhibition may provide a superior treatment option for patients with retinal vascular diseases and in particular those patients with diseases known to have a high inflammatory component such as DME, as well as in ocular inflammatory diseases such as uveitis.</span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="5">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
										<div class="container-fluid">
						<div class="toggle-chart-row toggle-chart-row--divider">
							<p></p>
						</div>
					</div>
														<div class="container-fluid">
											<div class="toggle-chart-row toggle-chart-row--title">
						<p><strong>KSI-601</strong> triplet biopolymer conjugate</p>
						</div>
										<div class="toggle-chart-row toggle-chart-row--content clearfix js-chart-content-toggle" data-target="6">
						<div class="toggle-chart-col toggle-chart-col--1">
							<button type="button" class="toggle-chart-btn"><span class="content-closed">+</span><span class="content-open">−</span><span class="sr-only">Toggle row content</span></button>
							<span class="js-chart-content-toggle-text">Dry age-related macular degeneration </span>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(25% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
				</div>
				<div class="toggle-chart-row-content toggle-chart-row-content-6">
					<div class="container-fluid">
						<div class="toggle-chart-mobile-headings">
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-clinical</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Pre-IND</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 1a/1b</span>
							</div>
							<div class="toggle-chart-heading toggle-chart-col">
								<span>Phase 3</span>
							</div>
						</div>
						<div class="toggle-chart-col toggle-chart-col--2 toggle-chart-bar-graph">
							<div class="toggle-chart-bar">
								<div style="width: 14px" class="toggle-chart-bar-partial"></div>
								<div style="width: calc(25% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-accomplished"></div>
								<div style="width: calc(0% - 14px)" class="toggle-chart-bar-partial toggle-chart-bar-ongoing"></div>
							</div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
							<div class="toggle-chart-col"></div>
						</div>
					</div>
											<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">What is Dry AMD?</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">Of the nearly 11 million individuals affected by AMD in the U.S., approximately 80-90% are the “dry” atrophic type. Dry age-related macular degeneration is characterized by deteriorating macula function caused by the formation of debris (drusen) on the retina causing the macula to deteriorate overtime. Dry AMD is thought to be caused by a combination of hereditary and environmental factors. Dry AMD patients can experience some vision loss and frequently experience substantial functional limitations, including vision fluctuations, loss of peripheral vision, and reduced night vision. </span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																	<div class="toggle-chart-row-content-section">
							<div class="container-fluid">
																																				<section class="row">
											<div class="col-xs-12 col-sm-10 col-sm-offset-1">
												<div class="pipeline-text-title centered-snippet ">
													<h1 class="underlined-title underlined-title-centered">How KSI-601 Can Help</h1>
													<div class="pipeline-text-title-text">
														<p><span style="font-weight: 400">The etiology of dry AMD and its advanced stages is multifactorial. Monotherapies evaluated for clinical utility in this disease have exhibited nominal or no improvement in clinical outcomes. The multiple pathogenic mechanisms in dry AMD initiation and progression include hyperinflammation, cell degeneration and atrophy, hypoxia, and dysfunctional lipid metabolism, among others. These warrant the development of therapies which can interface with these many disease mediators. Furthermore, different disease targets, which may be inside of the cell or located extracellularly, may require multiple therapeutic modalities; for example, a small molecule may be tailored for intracellular targets that are considered undruggable by antibodies. Therefore a single molecule triplet therapy enabled by our platform accommodates large and small molecules alike and facilitates, for the first time, the modulation of multiple distinct pathological processes in parallel.</span></p>
													</div>
												</div>
											</div>
										</section>
																																																																				</div>
						</div>
																<div class="pipeline-content-collapse js-chart-content-collapse" data-target="6">
						<div class="container-fluid">
							<button type="button" class="pipeline-content-collapse-btn">
								<span class="pipeline-content-collapse-symbol">−</span>
								Collapse Section
							</button>
						</div>
					</div>
				</div>
															</div>

				
		<div class="pipeline-landing-content-sections">
						<div class="toggle-chart-row-content-section">
					<div class="container-fluid">
																																																							<div id="section-7-1-1" class="anchor-link"></div>
																<section class="row">
									<div class="col-xs-12 col-sm-10 col-sm-offset-1">
										<div class="pipeline-text-title pipeline-text-icons centered-snippet">
											<h1 class="underlined-title underlined-title-centered">
												<span class="underlined-title-text">KSI-301 Product Vision</span>
											</h1>
											<div class="pipeline-text-title-text">
												<p><span style="font-weight: 400">KSI-301 is being investigated as an innovative anti-VEGF therapy to extend dosing and improve outcomes for patients with retinal vascular diseases. The KSI-301 clinical program is designed to run multiple pivotal studies in parallel and to support a full range of labeled dosing frequencies.&nbsp;</span></p>
											</div>
																																			<div class="pipeline-text-images-col container-breakout">
																										<div class="pipeline-text-images-icon-wrap">
															<div class="pipeline-text-images-icon">
																<div class="pipeline-text-images-icon-inner">
																	<img width="731" height="1024" src="https://kodiak.com/wp-content/uploads/sites/2/2020/10/201020_Website_Updates-01.png?w=731" class="attachment-large size-large" alt="" loading="lazy">																</div>
															</div>
																																<a href="https://ir.kodiak.com/static-files/eaf9070c-6733-4e4b-8a92-eba1719a4c8d">
																																	<p class="pipeline-text-icons-icon-title">DAZZLE<br>Primary data available</p>
																																	</a>
																																																												</div>
																											<div class="pipeline-text-images-icon-wrap">
															<div class="pipeline-text-images-icon">
																<div class="pipeline-text-images-icon-inner">
																	<img width="350" height="490" src="https://kodiak.com/wp-content/uploads/sites/2/2021/05/210518_Website_Updates-02.png?w=350" class="attachment-large size-large" alt="" loading="lazy">																</div>
															</div>
																																<p class="pipeline-text-icons-icon-title">DAYLIGHT<br>Enrollment Complete</p>
																																																																														<button class="btn btn-popup" data-toggle="modal" data-target="#icon-popup-1-1-2">Learn More →</button>
																<div class="modal fade info-popup" id="icon-popup-1-1-2" tabindex="-1" role="dialog">
																  <div class="modal-dialog container-fluid" role="document">
																	<button type="button" class="close" data-dismiss="modal" aria-label="Close">
																	  <div class="modal-x modal-x-a"></div>
																	  <div class="modal-x modal-x-b"></div>
																	</button>
																	<h2 class="info-popup-title">KSI-301 Product Vision</h2>
																	<h3 class="info-popup-hdr">Wet AMD</h3>
																	<div class="info-popup-img-text">
																																					<div class="info-popup-img-text-img">
																				<img width="400" height="434" src="https://kodiak.com/wp-content/uploads/sites/2/2021/05/210511_Website_Updates-02-1.png?w=400" class="attachment-kosci_modal_img size-kosci_modal_img" alt="" loading="lazy">																			</div>
																																				<div class="info-popup-img-text-content">
																			<h4 class="info-popup-subhdr">About the DAYLIGHT Study in Wet AMD</h4>
																			<p><span style="font-weight: 400">The Phase 3 DAYLIGHT study is a global, multi-center, randomized pivotal study designed to evaluate the efficacy and safety of high-frequency KSI-301 in patients with treatment-naïve wet AMD. Patients are randomized to receive either KSI-301 on a monthly dosing regimen or to receive standard-of-care aflibercept on a fixed dosing regimen of every 8-weeks after three monthly loading doses per its label. The DAYLIGHT study is intended to clarify the efficacy of KSI-301 to treat high need patients with wet AMD and, if successful, is intended to serve as the basis for approval in wet AMD with monthly dosing. Consistent with this intent to serve as an approval study, we are extending the length of DAYLIGHT, specifically extending the primary endpoint to the average of weeks 40, 44 and 48. DAYLIGHT has completed enrollment of approximately 550 patients worldwide. Additional information about the DAYLIGHT study (also called Study KS301P107) can be found on <a href="https://www.clinicaltrials.gov">www.clinicaltrials.gov</a> under Trial Identifier NCT04964089 (<a href="https://clinicaltrials.gov/ct2/show/NCT04964089">https://clinicaltrials.gov/ct2/show/NCT04964089</a>)</span></p>
																		  </div>
																	  </div>
																  </div>
																</div>
																													</div>
																											<div class="pipeline-text-images-icon-wrap">
															<div class="pipeline-text-images-icon">
																<div class="pipeline-text-images-icon-inner">
																	<img width="731" height="1024" src="https://kodiak.com/wp-content/uploads/sites/2/2020/10/201020_Website_Updates-03.png?w=731" class="attachment-large size-large" alt="" loading="lazy">																</div>
															</div>
																																<p class="pipeline-text-icons-icon-title">GLEAM and GLIMMER <br> Enrollment Complete</p>
																																																																														<button class="btn btn-popup" data-toggle="modal" data-target="#icon-popup-1-1-3">Learn More →</button>
																<div class="modal fade info-popup" id="icon-popup-1-1-3" tabindex="-1" role="dialog">
																  <div class="modal-dialog container-fluid" role="document">
																	<button type="button" class="close" data-dismiss="modal" aria-label="Close">
																	  <div class="modal-x modal-x-a"></div>
																	  <div class="modal-x modal-x-b"></div>
																	</button>
																	<h2 class="info-popup-title">KSI-301 Product Vision</h2>
																	<h3 class="info-popup-hdr">DIABETIC MACULAR EDEMA</h3>
																	<div class="info-popup-img-text">
																																					<div class="info-popup-img-text-img">
																				<img width="400" height="434" src="https://kodiak.com/wp-content/uploads/sites/2/2020/11/201029_Website_Updates-02.png?w=400" class="attachment-kosci_modal_img size-kosci_modal_img" alt="" loading="lazy">																			</div>
																																				<div class="info-popup-img-text-content">
																			<h4 class="info-popup-subhdr">About the GLEAM and GLIMMER Studies in Diabetic Macular Edema</h4>
																			<p><span style="font-weight: 400">The Phase 3 GLEAM and GLIMMER studies are global, multi-center, randomized pivotal studies designed to evaluate the durability, efficacy and safety of KSI-301 in patients with treatment-naïve diabetic macular edema. In each study, patients are randomized 1:1 to receive either KSI-301 or aflibercept. The KSI-301 arm is treated with a proactive, individualized dosing regimen of every 8-, 12-, 16-, 20- or 24 weeks (utilizing tight dynamic retreatment criteria) after three loading doses. The aflibercept arm is treated with a fixed dosing regimen of every 8-weeks after five monthly loading doses, per its label. Both studies completed enrollment of approximately 450 patients each worldwide in the first quarter of 2022. The primary endpoint for both studies is the average of weeks 60 and 64, and patients will be treated and followed for a total of two years. If successful, we expect that data from our GLEAM and GLIMMER studies will serve as the primary basis for approval of KSI-301 in our anticipated BLA submission.&nbsp; </span><span style="font-weight: 400">Additional information about the GLEAM study (also called Study KS301P104) and the GLIMMER study (also called Study KS301P105) can be found on <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> under Trial Identifiers NCT04611152 and NCT04603937, respectively (<a href="https://clinicaltrials.gov/ct2/show/NCT04611152">https://clinicaltrials.gov/ct2/show/NCT04611152</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT04603937">https://clinicaltrials.gov/ct2/show /NCT04603937</a>)</span></p>
																		  </div>
																	  </div>
																  </div>
																</div>
																													</div>
																											<div class="pipeline-text-images-icon-wrap">
															<div class="pipeline-text-images-icon">
																<div class="pipeline-text-images-icon-inner">
																	<img width="731" height="1024" src="https://kodiak.com/wp-content/uploads/sites/2/2020/10/201020_Website_Updates-04.png?w=731" class="attachment-large size-large" alt="" loading="lazy">																</div>
															</div>
																																<p class="pipeline-text-icons-icon-title">BEACON<br> Enrollment Complete</p>
																																																																														<button class="btn btn-popup" data-toggle="modal" data-target="#icon-popup-1-1-4">Learn More →</button>
																<div class="modal fade info-popup" id="icon-popup-1-1-4" tabindex="-1" role="dialog">
																  <div class="modal-dialog container-fluid" role="document">
																	<button type="button" class="close" data-dismiss="modal" aria-label="Close">
																	  <div class="modal-x modal-x-a"></div>
																	  <div class="modal-x modal-x-b"></div>
																	</button>
																	<h2 class="info-popup-title">KSI-301 Product Vision</h2>
																	<h3 class="info-popup-hdr">RETINAL VEIN OCCLUSION</h3>
																	<div class="info-popup-img-text">
																																					<div class="info-popup-img-text-img">
																				<img width="400" height="434" src="https://kodiak.com/wp-content/uploads/sites/2/2020/11/201029_Website_Updates-03.png?w=400" class="attachment-kosci_modal_img size-kosci_modal_img" alt="" loading="lazy">																			</div>
																																				<div class="info-popup-img-text-content">
																			<h4 class="info-popup-subhdr">About the BEACON Study in Retinal Vein Occlusion</h4>
																			<p><span style="font-weight: 400">The Phase 3 BEACON study is a global, multi-center, randomized study designed to evaluate the durability, efficacy and safety of KSI-301 in patients with treatment-naïve macular edema due to retinal vein occlusion, including both branch and central subtypes. Patients are randomized 1:1 to a KSI-301 arm or an aflibercept arm. In the first six months, the KSI-301 arm is treated with a proactive, fixed regimen which includes two monthly loading doses and then every 8-week treatment (including treatment four weeks prior to the 24-week primary endpoint). In the first six months, the aflibercept arm is treated with a fixed monthly regimen, per its label. In the second six months, patients in both groups will receive treatment on an individualized basis per protocol-specified criteria. Following this, patients can continue to receive KSI-301 for an additional six months on an individualized basis. The study completed enrollment of over 550 patients worldwide in the fourth quarter of 2021. The primary endpoint is at six months, and patients will be treated and followed for 18 months. If successful, data from the BEACON study are intended to serve as the basis for approval in RVO. Additional information about the BEACON study (also called Study KS301P103) can be found on </span><a href="http://www.clinicaltrials.gov/"><span style="font-weight: 400">www.clinicaltrials.gov</span></a><span style="font-weight: 400"> under Trial Identifier NCT04592419 </span><span style="font-weight: 400">(</span><a href="https://clinicaltrials.gov/show/NCT04592419"><span style="font-weight: 400">https://clinicaltrials.gov/show/NCT04592419</span></a><span style="font-weight: 400">). </span></p>
																		  </div>
																	  </div>
																  </div>
																</div>
																													</div>
																											<div class="pipeline-text-images-icon-wrap">
															<div class="pipeline-text-images-icon">
																<div class="pipeline-text-images-icon-inner">
																	<img width="731" height="1024" src="https://kodiak.com/wp-content/uploads/sites/2/2020/11/201112_Website_Updates-1-01.png?w=731" class="attachment-large size-large" alt="" loading="lazy">																</div>
															</div>
																																<p class="pipeline-text-icons-icon-title">GLOW<br>Recruiting Now</p>
																																																																														<button class="btn btn-popup" data-toggle="modal" data-target="#icon-popup-1-1-5">Learn More →</button>
																<div class="modal fade info-popup" id="icon-popup-1-1-5" tabindex="-1" role="dialog">
																  <div class="modal-dialog container-fluid" role="document">
																	<button type="button" class="close" data-dismiss="modal" aria-label="Close">
																	  <div class="modal-x modal-x-a"></div>
																	  <div class="modal-x modal-x-b"></div>
																	</button>
																	<h2 class="info-popup-title">KSI-301 Product Vision</h2>
																	<h3 class="info-popup-hdr">NON-PROLIFERATIVE DIABETIC RETINOPATHY</h3>
																	<div class="info-popup-img-text">
																																					<div class="info-popup-img-text-img">
																				<img width="400" height="436" src="https://kodiak.com/wp-content/uploads/sites/2/2021/10/Glow-Card.png?w=400" class="attachment-kosci_modal_img size-kosci_modal_img" alt="" loading="lazy">																			</div>
																																				<div class="info-popup-img-text-content">
																			<h4 class="info-popup-subhdr">About the GLOW Study in Non-proliferative Diabetic Retinopathy</h4>
																			<p>The Phase 3 GLOW study is a global, multi-center, randomized pivotal study designed to evaluate the efficacy and safety of KSI-301 in patients with treatment-naïve, moderately severe to severe non-proliferative diabetic retinopathy (NPDR). Patients are randomized to receive either KSI-301 on a once every six-month dosing regimen after three initiating doses or to receive sham injections. The study is expected to enroll approximately 240 patients worldwide. The primary endpoint is at one year and patients will be treated and followed for two years. Outcomes include changes in diabetic retinopathy severity, measured on a standardized photographic grading scale, and the rate of development of sight-threatening complications due to diabetic retinopathy. We believe KSI-301 has the potential to be a longest-interval therapeutic option for patients with diabetic retinopathy. If successful, we intend to include the results of the GLOW study in a supplemental BLA following our planned initial BLA submission. Additional information about the GLOW study (also called Study KS301P106) can be found on <a href="http://www.clinicaltrials.gov/" target="_blank" rel="noopener" data-saferedirecturl="https://www.google.com/url?q=http://www.clinicaltrials.gov/&amp;source=gmail&amp;ust=1634848452058000&amp;usg=AFQjCNFfYg70RGXbxD2iX4E8Nvt1M27NhQ">www.clinicaltrials.gov</a>&nbsp;under Trial Identifier NCT05066230&nbsp;(<a href="https://clinicaltrials.gov/ct2/show/NCT05066230" target="_blank" rel="noopener" data-saferedirecturl="https://www.google.com/url?q=https://clinicaltrials.gov/ct2/show/NCT05066230&amp;source=gmail&amp;ust=1634848452058000&amp;usg=AFQjCNFSNt3FYfEi5HNHnaJnkCGABnpOxQ">https://clinicaltrials.gov/ct2/show/NCT05066230</a>).</p>
																		  </div>
																	  </div>
																  </div>
																</div>
																													</div>
																									</div>
																					</div>
										<div class="pipeline-text-footnotes">
																					</div>
									</div>
								</section>
																																										<div id="section-7-1-2" class="anchor-link"></div>
								<section class="row">
									<div class="col-xs-12 col-sm-10 col-sm-offset-1">
										<div class="pipeline-text-title centered-snippet ">
											<h1 class="underlined-title underlined-title-centered">current medicines must be dosed on an intensive regimen <br>to maintain vision</h1>
											<div class="pipeline-text-title-text">
												<p>Current standard therapies for VEGF-mediated retinal vascular diseases require frequent and burdensome intravitreal injection&nbsp; of anti-VEGF proteins every 4 to 8 weeks<sup>1</sup>.</p>
<p><a href="https://kodiak.com/wp-content/uploads/sites/2/2020/08/Kodiak_Our-Pipeline_KSI-301-01-1.png"><img loading="lazy" class="alignnone wp-image-2044" src="https://kodiak.com/wp-content/uploads/sites/2/2020/08/Kodiak_Our-Pipeline_KSI-301-01-1.png" alt="" width="600" height="434"></a></p>
<p><span style="color: #000000"><sup>1. Per current anti-VEGF treatment labels<br>
2. Rosenfeld PJ et al; MARINA study group. N Engl J Med. 2006;355:1419-14313</sup></span></p>
											</div>
										</div>
									</div>
								</section>
																																																																													<div id="section-7-1-3" class="anchor-link"></div>
								<section class="row">
									<div class="col-xs-12 col-sm-10 col-sm-offset-1">
										<div class="pipeline-text-title centered-snippet ">
											<h1 class="underlined-title underlined-title-centered">Patients are undertreated and losing vision today<sup>1</sup></h1>
											<div class="pipeline-text-title-text">
												<p>Adherence to an intensive treatment regimen is difficult for patients and caregivers.<br>
Without frequent treatment, vision loss due to under-dosing can begin quickly and within 3 months.</p>
<p><a href="https://kodiak.com/wp-content/uploads/sites/2/2021/11/Kodiak_Our-Pipeline_KSI-301-02-03-1.png"><img loading="lazy" class="alignnone wp-image-2416 size-large" src="https://kodiak.com/wp-content/uploads/sites/2/2021/11/Kodiak_Our-Pipeline_KSI-301-02-03-1.png?w=1024" alt="" width="1024" height="236"></a></p>
<p><sup>1. Retrospective studies demonstrate that most patients receive ~5 injections a year.<br>
2. The AURA Study, adapted from Holz FG et al. BR J Ophthalmol 2015; 99 (2): 220-226.<br>
3. Adapted from Sierra AMD, Khanani A, et al. Ophthal. Retina 2020 Feb; 4(2):122-123. EMR= Electronic Medical Records</sup></p>
											</div>
										</div>
									</div>
								</section>
																																																																													<div id="section-7-1-4" class="anchor-link"></div>
								<section class="row">
									<div class="col-xs-12 col-sm-10 col-sm-offset-1">
										<div class="pipeline-text-title centered-snippet ">
											<h1 class="underlined-title underlined-title-centered">KSI-301 aims to maintain therapeutic activity for longer</h1>
											<div class="pipeline-text-title-text">
												<p style="text-align: center"><span style="font-weight: 400">KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. </span><span style="font-weight: 400">Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy and improves </span><span style="font-weight: 400">visual acuity outcomes.<br>
</span></p>
<p style="text-align: center">
</p><p><a href="https://kodiak.com/wp-content/uploads/sites/2/2022/06/Our-Science_Schematic-Graph-06062022b.png"><img loading="lazy" class=" wp-image-2511 aligncenter" src="https://kodiak.com/wp-content/uploads/sites/2/2022/06/Our-Science_Schematic-Graph-06062022b.png" alt="" width="848" height="564"></a></p>
											</div>
										</div>
									</div>
								</section>
																																																											</div>
				</div>
										</div>

	</article>

		  </main><!-- /.main -->
		  		</div><!-- /.content -->
	  </div><!-- /.wrap -->

	  <div class="modal fade" id="disclaimer-modal" tabindex="-1" role="dialog">
		<div class="modal-dialog container-fluid" role="document">
		  <button type="button" class="close" data-dismiss="modal" aria-label="Close">
			<div class="modal-x modal-x-a"></div>
			<div class="modal-x modal-x-b"></div>
		  </button>
		  <h1 class="underlined-title">Disclaimer</h1>
		  <p>Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.</p>
		</div>
	  </div>

	  
<footer id="site-footer" class="content-info" role="contentinfo">
	<div class="footer-primary">
		<div class="container-fluid">
			<div class="inner clearfix row">
				<div class="col-xs-12">
					<h3 class="widget-section-title">Kodiak Sciences INC.</h3>
											<div class="footer-address">
							<p>1200 Page Mill Road<br>
Palo Alto, CA 94304<br>
United States of America</p>
						</div>
									</div>
				<div class="col-md-4 col-sm-5 col-xs-6"><section class="widget text-2 widget_text">			<div class="textwidget"><p>Kodiak Sciences GMBH<br>
Dammstrasse 19<br>
6300 ZUG<br>
Switzerland</p>
<p><a href="mailto:info@kodiak.com">info@kodiak.com</a></p>
</div>
		</section></div>				<div class="col-md-4 col-sm-5 col-xs-6"><section class="widget text-3 widget_text">			<div class="textwidget"><p>Kodiak Sciences Valais GMBH<br>
Rottenstrasse 5<br>
3930 VISP<br>
Switzerland</p>
</div>
		</section></div>		<div class="footer-social clearfix col-xs-12">
		  <a href="https://www.linkedin.com/company/kodiak-sciences-inc" class="footer-social-icon footer-social-icon--linkedin">
			<span class="sr-only">LinkedIn</span>
		  </a>
		  <a href="https://twitter.com/kodiaksciences" class="footer-social-icon footer-social-icon--twitter">
			<span class="sr-only">Twitter</span>
		  </a>
		</div>
			<div class="copyright col-xs-12">
					  <span class="xs-break">Copyright © 2022</span>
			<span class="xs-break">Kodiak Sciences Inc.</span>
											<button class="btn-nostyle btn-disclaimer" data-toggle="modal" data-target="#disclaimer-modal">Disclaimer</button>
								</div>
				<a class="brand to-top" href="https://kodiak.com/">
					<svg width="484px" height="500px" viewBox="0 0 484 500" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
						<g id="Page-1" stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
							<g id="Kodiak_Footer_Logo-(1)" fill-rule="nonzero">
								<path d="M113.7,265.2 L0,500 L91.5,500 L197.6,273.5 C169.8,270.6 141.8,267.8 113.7,265.2" id="Shape" fill="#1C69A4"></path>
								<path d="M288.6,283.6 L390.4,500 L484,500 L385,295.6 C353.1,291.4 321,287.4 288.6,283.6" id="Shape" fill="#1C69A4"></path>
								<path d="M197.6,273.5 L240.6,181.6 L288.6,283.6 C321,287.4 353.2,291.4 385.1,295.6 L242,0 L113.7,265.2 C141.8,267.8 169.8,270.6 197.6,273.5" id="Shape" fill="#308DCC"></path>
							</g>
						</g>
					</svg>
		</a>
			</div>
		</div>
	</div>
</footer>
<script id="contact-form-7-js-extra">
var wpcf7 = {"api":{"root":"https:\/\/kodiak.com\/wp-json\/","namespace":"contact-form-7\/v1"}};
</script>
<script type="text/javascript" src="https://kodiak.com/_static/??-eJyVjc0OgjAQhF/IsiAqcDA+S2kXXWi3zbb49/RivBAPJh4n33wzcIuK2LjZYoIxgaWU4Ypsg4DgGRlF5yBKZs7ksfDExZg28ENbUAzuMZBz67oJnJEzRDefiRO8szZZDUG8amC9Rmzx/u3lC/oFT8GSnlA+l8kIxZzAB4vC9BS1NbY2Jbb/6ZpYNWXfVA32i3nyx+qwr7u6a3ft+ALQZmrl"></script><script src="https://stats.wp.com/e-202224.js" defer=""></script>
<script>
	_stq = window._stq || [];
	_stq.push([ 'view', {v:'ext',j:'1:11.0',blog:'195614896',post:'840',tz:'0',srv:'kodiak.com',hp:'vip'} ]);
	_stq.push([ 'clickTrackerInit', '195614896', '840' ]);
</script>
	</div>
  

<img src="https://pixel.wp.com/g.gif?v=ext&amp;j=1%3A11.0&amp;blog=195614896&amp;post=840&amp;tz=0&amp;srv=kodiak.com&amp;hp=vip&amp;host=kodiak.com&amp;ref=&amp;fcp=1210&amp;rand=0.7174920078073659" alt="" width="6" height="5" id="wpstats"></body></html>